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The molecular-mimicry theory proposes that immune crossreactiv-
ity betweenmicrobial and self-antigen is the initiating event in the
activation of autoaggressive immune responses leading to auto-
immune disease. In support of this possibility, it is now accepted
that T cell recognition of antigen is highly degenerate. However, it
is to be expected that the immune system would have evolved
mechanisms to counter such a potential danger. We studied the
influence of CD4CD25 regulatory T cells (Treg) on the ability of
suboptimal T cell receptor ligands to provoke autoimmunity. By
using CD4 T cell-driven experimental autoimmune encephalomy-
elitis as amodel, it was found that depletion of CD4CD25Foxp3
Treg allowed pathology to develop in response to suboptimal T cell
stimulation. These data demonstrate the importance of Treg in
raising the threshold of triggering of autoreactive T cell responses,
thus limiting the risk of autoimmune disease due to molecular
mimicry.
experimental autoimmune encephalomyelitis (EAE)  multiple sclerosis 
regulation  tolerance
Extensive flexibility in T cell receptor (TCR) recognition ofpeptide–MHC (pMHC) complexes has been proposed to be
essential to provide effective immune surveillance of all possible
pathogen-derived pMHC complexes (1). The logical extension of
this cross-reactivity is that the peripheral T cell repertoire should
contain a sizeable population of cells that are capable of
responding in a cross-reactive manner to both pathogen-derived
antigens (Ags) and self-molecules. This concept is at the heart of
the molecular-mimicry theory, in which self-reactive T cells,
activated initially by infectious pathogens, subsequently provoke
a self-destructive response in an organ expressing a cross-
reactive self-Ag (2). However, there is considerable debate over
the validity of this theory as a general mechanism for the
induction of autoimmune disease (3), and mechanisms that limit
this potential risk are likely to exist. Naturally occurring regu-
latory T cells (Treg) may have a role by raising the activation
threshold of T cell responses, potentially providing one mecha-
nism by which weakly self-reactive T cells can be maintained in
the T cell repertoire without inducing overt autoimmunity.
Treg activity is enriched in the subset of CD4 T cells
expressing CD25 in mice (4), rats (5), and humans (6), leading
to the now widespread use of this marker to define a naturally
occurring population of Treg. The influence of Treg on periph-
eral tolerance is shown most vividly by the widespread autoim-
mune and inflammatory lesions that are evident in humans and
mice that lack these cells because of mutations in the Treg-
specific transcription factor Foxp3 (7–10). Although conclusive
evidence regarding the specificity of CD4CD25Foxp3 Treg
remains elusive, they are known to have a broad TCR repertoire
(11), and there is evidence to suggest that CD25 Treg devel-
oping in the thymus are selected to have high affinity for self-Ags
expressed on thymic epithelium (12–14). Negative selection in
the thymus should ensure that the only cells remaining in the
mature T cell repertoire have low reactivity to self-Ag, but of
these, Treg will be biased toward higher affinity to self than
non-Treg, perhaps because of their greater resistance to agonist-
induced clonal deletion (15). Also, it is known that the Ag dose
that is required to activate suppressive function in TCR trans-
genic CD25 Treg is lower than that required for the prolifer-
ation of CD25 T cells of identical specificity (11). Therefore, it
is generally envisaged that Treg cells with high sensitivity for self
would impose a dominant control on other potential autoag-
gressive cells with lower sensitivity for self while not preventing
high-affinity responses to foreign Ags. In this regard, it is also
known that high Ag dose andor strong costimulation, as would
be associated with the presence of infectious agents, can allow
responder T cells to escape Treg-mediated suppression (16–18).
This model predicts that a decrease in the number or function of
Treg would increase the risk of self-reactive T cells becoming
pathogenic and inducing autoimmune disease in response to
suboptimal TCR ligation.
We tested this hypothesis in the setting of murine experimen-
tal autoimmune encephalomyelitis (EAE), induced in response
to the I-Au-restricted Ac1-9 epitope of myelin basic protein
(MBP). Altered peptide ligands (APLs) have been defined for
which Ac1-9-reactive T cells have a range of sensitivities that are
either higher or lower than the sensitivity shown for the WT
Ac1-9 peptide (19), and they are referred to as superagonists and
subagonists, respectively. Immunization with subagonist APL
was used as a surrogate approach to activation of self-reactive T
cells by infectious cross-reactive Ag. In vitro, Ac1-9-reactive Tg4
TCR transgenic CD25 Treg had a purely quantitative effect on
the proliferation of responder Tg4 CD25 cells, raising the
dose–response curve of both subagonist and superagonist pep-
tides by 100-fold. In effect, CD25 Treg resulted in efficient
suppression of CD25 responses to weak agonist APL over a
wider concentration range compared with responses to WT or
superagonist peptides. In vivo, depletion of CD25 Treg pre-
vented efficient recovery from Ac1-9-induced EAE in H-2u
mice. Moreover, CD25 Treg depletion allowed EAE to be
induced with a subagonist Ac1-9 APL that normally resulted in
only poor EAE induction. These data identify a role for CD25
Treg in preventing the conversion of a suboptimal antigenic
stimulation into an overt autoaggressive response. In this model,
this effect was not associated with dramatic changes in the
number or cytokine-producing capacity of transferred Ac1-9-
specific TCR transgenic Tg4 T cells in vivo.
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Methods
Mice and Peptides.B10.PL (H-2u), B10.PLxSJL (H-2uxs), Tg4mice
(expressing a transgenic Ac1-9-reactive TCR; ref. 20) and
Tg4.Ly5.1 mice (backcrossed more than five generations onto to
the Tg4 background) were bred and maintained in specific-
pathogen-free conditions at the University of Edinburgh. The
Ac1-9 peptide (Ac-ASQKRPSQR) and APL with substitutions
at residues 3 or 4 were synthesized by Advanced Biotechnology
Centre (Imperial College, London).
T Cell Purification. CD4 T cells were enriched from spleen and
lymph nodes (cervical, mesenteric, brachial, axillary, inguinal,
and iliac) by negative selection involving incubation on ice with
the following mixture of Abs (purified from hybridomas):
RAB632 (anti-B220), 53-6.72 (anti-CD8), M170 (anti-Mac1),
and M5114.15.2 (anti-MHC class II), followed by washing and
incubation with M450 sheep anti-rat IgG Dynabeads (Dynal,
Bromborough, U.K.). Cells were then fractionated according to
CD25 expression by using anti-CD25-phycoerythrin (PE) (clone
7D4, Miltenyi Biotec, Auburn, CA), followed by incubation with
anti-PE microbeads (Miltenyi Biotec) and separation on col-
umns according to the manufacturer’s instructions. Highly
pure (95%) CD4CD25 cells from Tg4 mice were obtained
after further cell sorting on a FACStar flow cytometer (BD
Biosciences).
In Vitro Proliferation Assay. Cells were cultured in triplicate in
U-bottomed 96-well plates in RPMI medium 1640 (GIBCO, In-
vitrogen) supplementedwith 5%heat-inactivatedFCS (Sigma), 100
unitsml penicillin, 100 gml streptomycin, 2 mM L-glutamine, 1
mM sodium pyruvate, and 50 M 2-mercaptoethanol (all obtained
fromGIBCO). Responder CD4CD25 Tg4 T cells were added at
2.5  104 cells per well with or without the same number of
CD4CD25 Tg4 cells and with 5 104 irradiated (30 Gy) B10.PL
splenocytes as Ag-presenting cells and were stimulated with Ac1-9
WT or APL peptide. We added 0.5 Ci (1 Ci  37 GBq)
3[H]thymidine (Amersham Biosciences) for the last 18 h of a 90-h
culture period. Data are shown as mean  SD of triplicate wells.
In Vivo Depletion of CD25 Cells. Endogenous CD25 cells were
depleted from mice 2 or 3 days before induction of EAE by i.p.
injection with 1 mg of the anti-CD25 Ab PC61(rat IgG1). Control
mice received an i.p. injection of 1 mg of MAC49 (rat IgG1,
anti-phytochrome). Confirmation of CD25 cell depletion by PC61
was determined by staining peripheral blood of all mice 2 or 3 days
after treatment with an Ab that recognizes a different epitope of
CD25 (7D4), and it always resulted in90%CD25 cell depletion.
Induction of EAE. EAE was induced by s.c. immunization with 200
g of eitherWTAc1-9 or the indicatedAPLemulsified in complete
Freund’s adjuvant (Sigma) and injected in 50l per leg in each hind
leg. Pertussis toxin (200 ng; Health Protection Agency, Porton
Down,U.K.) was administered i.p. on the same day and 2 days later.
In some experiments, 2.5  105 CD4CD25 cells purified from
Tg4.Ly5.1 mice were transferred i.v. to B10.PL mice 1 day before
EAE induction. Mice were monitored daily for clinical signs of
EAE by using the following scores: 0, healthy; 1, limp tail; 2,
impaired gaitrighting reflex; 3, partial hind limb paralysis; 4, total
hind limb paralysis, or partial hind limb paralysis and front weak-
ness; 5, total hind limb paralysis plus front leg weakness; and 6,
moribund or dead. Comparison of disease incidencewas performed
by the Fisher’s exact test, and overall disease burdens were com-
pared by the Mann–Whitney U test.
Isolation of Spinal Cord Infiltrating Cells. Mice were killed by CO2
asphyxiation and perfused with cold PBS. Spinal cords were
removed by intrathecal hydrostatic pressure, chopped into small
pieces, and digested for 30 min at 37°C with 2.5 mgml colla-
genase (Worthington) and 1 mgml DNase (Sigma) before
mechanical disaggregation. Cells were isolated from the inter-
face of a 30:70% discontinuous Percoll gradient after centrifu-
gation for 20 min at 2,000  g.
Flow Cytometry. Cells were stained with appropriately titrated
Abs for 20 min on ice and washed with PBS plus 2% FCS. For
intracellular cytokine staining, cells were restimulated ex vivo
with phorbol 12-myristate 13-acetate (PMA; 10 ngml) and
ionomycin (1 gml) for 5 h in the presence of GolgiStop (BD
Biosciences). Cells were surface-stained and then fixed and
permeabilized by using BD CytofixCytoperm according to the
manufacturer’s instructions before staining for intracellular cy-
tokines by using the following mAbs: IL-2–PE, IL-10–PE, IFN-
–PE, IL-17–PE, IL-4–PE, or appropriate isotype control mAbs
(all purchased from BD Biosciences). Foxp3 staining was per-
formed by using a Foxp3 staining set (eBioscience, San Diego;
Insight Biotechnology, Wembley, U.K.) according to the man-
ufacturer’s instructions. Data were acquired on a FACSCaliber
cytometer (BD Biosciences) and analyzed by using FLOWJO
software (Treestar, San Carlos, CA).
Results
CD4CD25 Cells Increase the Threshold for Tg4 T Cell Proliferation in
Vitro in Response to Ac1-9 APL. The molecular requirements for
Tg4 T cell recognition of the Ac1-9–I-Au complex have been well
characterized in previous studies. Briefly, residues 4 and 5 of this
peptide interact with MHC class II Au (21), whereas positions 3
and 6 are important TCR contact residues (19, 22). Ac1-9 binds
weakly to I-Au because the Lys at position 4 fits poorly with the
large hydrophobic P4 pocket of Au (23, 24); consequently, most
position-4 APL show stronger Au-binding affinities and act as
superagonists for Ac1-9-reactive T cells (this characteristic is
particularly true of the Tyr-4 and Ala-4 APLs) (19). Position-6
APLs cannot stimulate Tg4 T cells, whereas several position-3
APLs act as subagonist ligands for Tg4 cells, with the following
hierarchy of responsiveness: Gln-3  Met-3  Phe-3 (22, 25).
Studies have shown (22) that immunization of nontransgenic
mice with these APL largely failed to induce EAE. Therefore, in
this study, the Met-3 and Phe-3 APLs served as surrogate
cross-reactive subagonists.
Our initial analysis of the impact of Treg on the strength of T
cell stimulation was an in vitro assessment of the response of Tg4
T cells to WT Ac1-9 and various APLs (Fig. 1). Purified CD25
and CD25 Tg4 T cells were cultured, either alone or in
combination, with the peptide Ags. As shown in another TCR
transgenic system (17), Tg4 CD25 cells were able to inhibit
responses to WT Ac1-9 at suboptimal doses, but as the dose
increased, the level of suppression dropped, with only 50–75%
suppression at saturating concentrations of Ac1-9 (100M) (Fig.
1A). Two findings arose from the analysis of responses to
superagonist APL (Ala-4 and Tyr-4). First, the purified CD25
Tg4 cells remained hypoproliferative even under this intense
TCR stimulation (Fig. 1 B and C). Second, Tg4 CD25 Treg
suppressed CD25 Tg4 cell activation by the superagonists,
although, as with the WT Ac1-9 peptide, suppression was
diminished at higher APL concentrations (Fig. 1 B and C). This
result demonstrated that, even under conditions of supraoptimal
TCR ligation, Treg cells could still suppress their CD25 coun-
terparts. Stimulation of Tg4 cells with subagonist Met-3 and
Phe-3 APLs resulted in essentially the same pattern of reduced
responsiveness at lower peptide concentrations in the presence
of CD25 Treg (Fig. 1 D and E). Because CD25 T cell
proliferation required higher concentrations of the subagonist
APL compared with WT Ac1-9, good suppression was achieved
by CD25 Treg at most concentrations of subagonist APL (Fig.
1F). Therefore, the overall effect of CD25 Treg under these
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culture conditions was to shift the activation requirements of the
CD25 cells by 2-log (i.e., 100 times higher doses of peptide were
required to give a similar level of proliferation in the presence of
Treg cells). This effect was consistent whether the WT, super-
agonist, or subagonist peptides were used. Therefore, in this
respect, the suppressive activity of Treg in this system appears to
be entirely quantitative.
CD4CD25Foxp3 Cells Limit EAE Pathology. Our in vitro studies
provided some important information; at high Ag loads (such as
might be expected in draining lymph nodes after immunization),
CD25 Treg cell suppression was incomplete when the Ag was
WT Ac1-9 but still intact when the Ag was a subagonist. This
information led to the hypothesis that the reason that the
subagonist APLs fail to induce EAE is because Treg function is
dominant in this situation. This possibility was tested in vivo by
depletion of CD25 cells from B10.PL or B10.PLxSJL mice
before immunization with either WT Ac1-9 or the Met-3 APL.
Administration of the PC61 anti-CD25 Ab resulted in the
depletion of90% of CD4CD25 T cells within 2 or 3 days (data
not shown) and substantial reduction of their numbers for at least
3weeks after treatment, with a gradual recovery to normal numbers
by5 weeks after treatment (Fig. 2). Analysis of Foxp3 expression
(the transcription factor that is the only known unique identifier of
Treg, both CD25 and CD25; ref. 26) demonstrated conclusively
that the PC61 Ab does deplete CD25 Treg, rather than simply
inducing down-regulation of CD25 expression on these cells. As
shown in Fig. 2, the number of CD25Foxp3 cells was greatly
reduced after PC61 treatment, without resulting in a corresponding
increase in CD25-Foxp3 cells compared with control mice. Im-
portantly, these results also demonstrate that as much as half of the
total Treg pool, as defined by Foxp3 expression (26), remained
undepleted after PC61 treatment because of the lack of CD25
expression (Fig. 2).
The in vivo depletion of CD25 Treg cells resulted in EAE of
substantially increased severity, both in terms of mean clinical
scores and mortality, compared with control mice after immu-
nization with WT Ac1-9. This finding was true for both B10.PL
(Fig. 3A) and B10.PLxSJL (Fig. 3B) strains of mice, with
B10.PLxSJL succumbing to more severe disease than B10.PL.
CD25Treg depletion also resulted in impaired natural recovery
from EAE, which was particularly noticeable in the B10.PL
strain in which there was less mortality, but had no effect on the
kinetics of disease onset (Fig. 3 A and B). These data reveal a
clear role for endogenous CD25 Treg in limiting autoimmune
pathology induced with the Ac1-9 peptide.
More importantly, CD25 depletion allowed mice to become
susceptible to EAE development after immunization with the
subagonist Ac1-9(Met-3) APL that normally induces EAE very
poorly and with delayed onset. There was a significant increase
in the incidence of EAE after CD25 depletion in both B10.PL
and B10.PLxSJL mice (Fig. 3 C and D). This effect was most
striking in the B10.PL mice, as these mice were less susceptible
to Ac1-9(Met-3)-induced EAE than the B10XSJL strain. The
lower mean clinical score of mice after subagonist peptide
immunization compared with WT reflects this difference in
EAE incidence, rather than a difference in EAE severity (i.e.,
mice that developed EAE reached the same maximum severity
as those receiving WT peptide). These data show an important
role of CD25 Treg in preventing the occurrence of overt
autoimmune disease after exposure to a weakly cross-reactive
exogenous Ag.
Fig. 1. CD4CD25 Tg4 cells raise the threshold for CD4CD25 Tg4 prolif-
eration in vitro. (A–E) CD4CD25 and CD4CD25 Tg4 cells were cultured
either alone or in combination (at 1:1) in the presence of irradiated B10.PL
Ag-presenting cells and the indicated concentration of WT Ac1-9 or APL.
Proliferation was measured by 3[H] thymidine incorporation during the last
18 h of a 90-h culture period, and the results are shown as mean  SD of
triplicate wells. (F) Results in A–E are shown as the percentage of suppression
in the presence of Treg.
Fig. 2. PC61 Ab depletes CD25Foxp3 cells in vivo. B10.PL mice were
injected i.p. with 1 mg of either PC61 or isotype control Ab (MAC49), and EAE
was induced 3 days later by using Ac1-9. CD25 and Foxp3 expression were
examined on gated CD4 lymphocytes from draining lymph nodes (A and B)
and spleen (C and D) at various times after immunization. Results are shown
as the mean  SD of three to six mice per group at each time point.
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The Effects of CD25 Cell Depletion on Transferred Ac1-9-Reactive Tg4
CD4CD25 T Cells in Vivo. In an attempt to define the effects of
CD25 Treg on the expansion and differentiation of pathogenic
Ac1-9-reactive CD4T cells in vivo, we transferred CD4CD25
cells from Tg4Ly5.1 mice into B10.PL (Ly5.1) recipient mice.
The Tg4 cells were confirmed to be playing an important
pathogenic role in this transfer model as their presence at low
cell doses (1–3 105) accelerated disease onset, with higher cell
doses resulting in increased mortality (Fig. 4A). In this Tg4
transfer model, depletion of the host CD25 Treg again resulted
in more severe EAE after transfer of low Tg4 cell numbers (Fig.
4B). To examine the effects of host CD25 Treg on Tg4 cells in
vivo, cells from spleen and lymph nodes draining the site of
immunization (inguinal and iliac), as well as the effector site
(spinal cord), were obtained from PC61 or control Ab treated
mice after immunization with WT peptide. A massive expansion
of Tg4 cells was seen in the draining lymph nodes and spleen on
day 6 after immunization, at a time before clinical signs of
disease were apparent, which waned rapidly at later time points
(Figs. 4B and 5). At the peak of EAE, there was a great
enrichment of Tg4 cells in the spinal cord (Fig. 5). However,
PC61 treatment did not significantly affect either the percentage
(not shown) or the absolute number of Tg4 cells (Fig. 5) at any
of the time points analyzed, either in the lymphoid tissue or the
CNS. Tg4 cells produced enriched levels of IL-17, IL-2 and
IFN- compared to host cells in the spleen, lymph nodes and
spinal cord, and little IL-10 or IL-4 (Fig. 5 and data not shown).
However, PC61 treatment was again found to have little effect
on the differentiation of Tg4 cells with respect to their cytokine-
producing capacity. These data using Tg4 cell function as the
readout therefore argue against a simple effect of CD25 Treg
on the expansion, migration or differentiation of pathogenic T
cells, despite their clear influence on pathology.
Discussion
Flexibility in TCR recognition of pMHC complexes appears to
be essential to provide immune surveillance against a universe
of potential pathogens (1). This f lexibility obviously carries the
potential risk of autoaggression triggered by molecular mimicry.
For the advantages of TCR crossreactivity to outweigh this
hazard, the immune system must limit the scope for it to occur.
CD25 Treg have been shown to suppress effector cell activation
under suboptimal conditions in vitro (17). Here, we report that
this principle can be extended to a disease setting in vivo. By
using a CD4 T cell-mediated disease that targets the CNS, we
found that CD25 Treg cells limit progression to overt autoim-
mune disease after T cell triggering by suboptimal TCR ligands.
Thus, with weakly cross-reactive initiating Ags, the presence or
absence of CD25 Treg is crucial in determining whether mice
succumb to autoimmune disease.
Depletion of endogenous CD25 Treg also impaired the
recovery of H-2u mice from EAE induced with WT Ac1-9. This
result confirms and extends observations from other models of
EAE, in which endogenous CD25 Treg were found to have an
important role in limiting pathology induced with WT Ag
(27–29). Note that the treatment of mice with PC61, which was
confirmed in this study to genuinely deplete CD25Foxp3
Treg, removes only approximately half of the total Foxp3 Treg
pool, with a significant population of Foxp3CD25 cells still
remaining. Currently we have no way to deplete these CD25-
Foxp3 Treg, making their role in the regulation of EAE less
amenable to investigation. Our assumption would be that the
removal of all Foxp3 cells would result in an even more
profound effect on EAE development triggered by weak anti-
genic stimulation.
Our results conclusively show a role for CD25 Treg in
limiting autoimmune disease at the margins of T cell activation.
However, it is not clear at what level this regulation is exerted
Fig. 3. In vivo depletion of CD25 Treg exacerbates clinical signs of EAE and
potentiates EAE induction with a subagonist APL. B10PL (A and C) and
B10PLxSJL (B and D) mice were injected i.p. with 1 mg of PC61 (filled symbols)
or isotype control Ab (MAC49; open symbols). EAE was induced by immuni-
zation 2 or 3 days later with 200 g ofWTAc1-9 (A and B) orMet-3 APL (C and
D). For B10.PL mice (A and C), data were pooled from two experiments (n 
11). For B10.PLxSJL mice, data were pooled from three (n 16; B) or four (n
23–28; D) experiments. Mortality rates in response to WT peptide for PC61
and Mac49-treated mice, respectively, were 311 and 011 (A) and 916 and
416 (B) (with a disease incidence of 91–100% for each group). The numbers
in C andD indicate the disease incidence in each group. PC61 treatment led to
a significant increase in cumulative disease scores in each case (P  0.0001,
one-tailed Mann–Whitney U test), and it resulted in a significant increase in
disease incidence in response to subagonist APL (C andD) (P 0.05, one-tailed
Fisher’s exact test).
Fig. 4. Ac1-9-reactive Tg4 cells are pathogenic in vivo. (A) Purified
CD4CD25 Tg4.Ly5.1 cells were injected i.v. into B10.PL mice at the dose
indicated 1 day before EAE induction with 100 g of Ac1-9. (B) B10.PL mice
were given either PC61 or isotype control Ab 2 days before receiving 2.5 105
CD4CD25 Tg4 cells. EAE was induced 1 day later with 100 g of Ac1-9 (16
mice per group). There was a significant increase in the cumulative disease
score of PC61-treated mice (one-tailed Mann–Whitney U test; P  0.0001).
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(i.e., initial T cell activation, T cell differentiation and effector
function, or T cell entry into the tissues). A functional role for
Treg within the target organ is supported by our recent obser-
vation that CD25Treg accumulation in the CNS correlates with
recovery from EAE (29). Alternatively, Treg may be active
during the initial T cell priming events, and, in their absence, an
altered and more virulent T cell population may expand. This
alteration could be quantitative (either more T cells or cells with
increased sensitivity for the self-Ag) or qualitative (increased
production of inflammatory cytokines or altered expression of
adhesion molecules or chemokine receptors). Studies in which
TCR transgenic T cells have been tracked in vivo in the presence
or absence of cotransferred Ag-specific CD25 Treg have re-
ported an influence of the CD25 Treg on the later expansion
but not the cytokine production of Ag-specific T cells (30), or an
effect on cytokine production but not T cell expansion by
responder T cells (31).
Our data from Tg4 T cell transfers into CD25 Treg-depleted
mice revealed no difference in either the early or late expansion of
Ac1-9-reactive cells after immunization in either the priming or
effector site. Analysis of cytokine production by the transferredTg4
cells also showed no significant qualitative or quantitative shifts as
a result of CD25 Treg depletion. Similarly, we lack evidence to
show that PC61 treatment enabled Tg4 cells to respond to the
subagonist peptide in vivo (data not shown). It still remains possible
that Treg depletion may alter the ability of Tg4 cells to produce
effector cytokines in vivo, despite the apparent lack of any effect ex
vivo under the experimental conditions that we used. It is also
possible that the suppression by Treg of other undefined effector
mechanisms used by Tg4 cells is more important than the suppres-
sion of cytokine production in this model. Although Tg4 cells
clearly enhance pathology in the transfer model, it is probable that
polyclonal host CD4 T cells also contribute to EAE pathogenesis.
The Tg4 TCR is only one receptor from a heterogeneous Ac1-9-
reactive repertoire. In particular, there are T cells bearing TCRs of
higher affinity than Tg4 (32) and these would be predicted to have
lower thresholds for activation than Tg4 cells. Therefore, Treg
depletion may preferentially release these cells from normal reg-
ulatory control, allowing the development of overt disease that we
see in response to subagonist immunization. In the absence of the
appropriate TCR transgenic mouse, we have no way of tracking
such cells. Alternatively, other cells of the immune systemmay also
be an important target of Treg function, including cells of the innate
immune system (33). Despite substantial research in many models,
the exact mechanisms used by CD25 Treg to mediate their
suppressive effects remain enigmatic.
The immune systemmust achieve a difficult balance between the
TCR crossreactivity necessary for effective immune surveillance
and the risk of provoking a destructive response against self. The
accumulating data point to a multilayered control. Negative selec-
tion deletes most (but not all) T cells bearing TCRs with high
affinity for self-pMHC. Clearly, an absolute deletional mechanism
for self-tolerance would be wasteful; T cells with self-reactivity
below a certain sensitivity pose little threat. Moreover, such a
mechanism would provide an extremely porous peripheral T cell
repertoire if most T cells have some residual ability to recognize
self-pMHC. The data presented here demonstrate a role for Treg
in reducing the likelihood of an autoaggressive response as a
consequence of crossreactivity with an infectious agent.
We thank Andrew Sanderson for flow cytometric cell sorting. This work
was supported by theWellcome Trust and theMedical Research Council
(MRC). S.M.A. is an MRC Senior Research Fellow.
1. Mason, D. (1998) Immunol. Today 19, 395–404.
2. Fujinami, R. S. & Oldstone, M. B. (1989) Immunol. Res. 8, 3–15.
3. Benoist, C. & Mathis, D. (2001) Nat. Immunol. 2, 797–801.
4. Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M. & Toda, M. (1995)
J. Immunol. 155, 1151–1164.
5. Stephens, L. A. & Mason, D. (2000) J. Immunol. 165, 3105–3110.
6. Stephens, L. A., Mottet, C., Mason, D. & Powrie, F. (2001) Eur. J. Immunol.
31, 1247–1254.
7. Hori, S., Nomura, T. & Sakaguchi, S. (2003) Science 299, 1057–1061.
8. Fontenot, J. D., Gavin, M. A. & Rudensky, A. Y. (2003) Nat. Immunol. 4,
330–336.
9. Khattri, R., Cox, T., Yasayko, S. A. & Ramsdell, F. (2003) Nat. Immunol. 4,
337–342.
10. Gambineri, E., Torgerson, T. R. & Ochs, H. D. (2003) Curr. Opin. Rheumatol.
15, 430–435.
11. Takahashi, T., Kuniyasu, Y., Toda, M., Sakaguchi, N., Itoh, M., Iwata, M.,
Shimizu, J. & Sakaguchi, S. (1998) Int. Immunol. 10, 1969–1980.
12. Jordan, M. S., Boesteanu, A., Reed, A. J., Petrone, A. L., Holenbeck, A. E.,
Fig. 5. Effects of CD25 Treg depletion on Tg4 cell expansion and cytokine
production in vivo. Tg4.Ly5.1 cells fromtheexperiment shown in Fig. 4Bwere
enumerated by flow cytometry in the draining lymph nodes (inguinal and
iliac), spleen, and spinal cord of mice on days 6, 11, 19, and 34 after EAE
induction. Cytokine production by Tg4.Ly5.1 cells was measured by intracel-
lular staining for flow cytometry after 5 h of ex vivo stimulation of cells with
phorbol 12-myristate 13-acetate (PMA) and Ionomycin. Results are shown as
mean  SD of three to six mice per group. Tg4 numbers in control mice that
were immunized with CFA alone were 0.09  105 in spleen, 0.06  105 in
lymph nodes, and0.006 105 in the spinal cord at all time points (data not
shown). Sufficient numbers of Tg4 cells for analysis of cytokine production
were available from the spinal cord only on day 11.
17422  www.pnas.orgcgidoi10.1073pnas.0507454102 Stephens et al.
Lerman, M. A., Naji, A. & Caton, A. J. (2001) Nat. Immunol. 2,
301–306.
13. Hsieh, C.-S., Liang, Y., Tyznik, A. J., Self, S. G., Liggitt, D. & Rudensky, A. Y.
(2004) Immunity 21, 267–277.
14. Bensinger, S. J., Bandeira, A., Jordan, M. S., Caton, A. J. & Laufer, T. M.
(2001) J. Exp. Med. 194, 427–438.
15. van Santen, H.M., Benoist, C. &Mathis, D. (2004) J. Exp. Med. 200, 1221–1230.
16. Ermann, J., Szanya, V., Ford, G. S., Paragas, V., Fathman, C. G. & Lejon, K.
(2001) J. Immunol. 167, 4271–4275.
17. George, T. C., Bilsborough, J., Viney, J. L. & Norment, A. M. (2003) Eur.
J. Immunol. 33, 502–511.
18. Pasare, C. & Medzhitov, R. (2003) Science 299, 1033–1036.
19. Anderton, S., Burkhart, C., Metzler, B. &Wraith, D. (1999) Immunol. Rev. 169,
123–137.
20. Liu, G. Y., Fairchild, P. J., Smith, R. M., Prowle, J. R., Kioussis, D. & Wraith,
D. C. (1995) Immunity 3, 407–415.
21. Wraith, D. C., Smilek, D. E., Mitchell, D. J., Steinman, L. & McDevitt, H. O.
(1990) Int. Rev. Immunol. 6, 37–47.
22. Wraith, D. C., Bruun, B. & Fairchild, P. J. (1992) J. Immunol. 149, 3765–3770.
23. Pearson, C. I., Gautam, A. M., Rulifson, I. C., Liblau, R. S. & McDevitt, H. O.
(1999) Proc. Natl. Acad. Sci. USA 96, 197–202.
24. Lee, C., Liang, M. N., Tate, K. M., Rabinowitz, J. D., Beeson, C., Jones, P. P.
& McConnell, H. M. (1998) J. Exp. Med. 187, 1505–1516.
25. Anderton, S. M., Manickasingham, S. P., Burkhart, C., Luckcuck, T. A.,
Holland, S. J., Lamont, A. G. & Wraith, D. C. (1998) J. Immunol. 161,
3357–3364.
26. Fontenot, J. D., Rasmussen, J. P., Williams, L. M., Dooley, J. L., Farr, A. G.
& Rudensky, A. Y. (2005) Immunity 22, 329–341.
27. Montero, E., Nussbaum, G., Kaye, J. F., Perez, R., Lage, A., Ben-Nun, A. &
Cohen, I. R. (2004) J. Autoimmun. 23, 1–7.
28. Zhang, X., Koldzic, D. N., Izikson, L., Reddy, J., Nazareno, R. F., Sakaguchi,
S., Kuchroo, V. K. & Weiner, H. L. (2004) Int. Immunol. 16, 249–256.
29. McGeachy, M. J., Stephens, L. A. & Anderton, S. A. (2005) J. Immunol. 175,
3025–3032.
30. Klein, L., Khazaie, K. & von Boehmer, H. (2003) Proc. Natl. Acad. Sci. USA
100, 8886–8891.
31. Sarween, N., Chodos, A., Raykundalia, C., Khan, M., Abbas, A. K. & Walker,
L. S. (2004) J. Immunol. 173, 2942–2951.
32. McCue, D., Ryan, K. R., Wraith, D. C. & Anderton, S. M. (2004) J. Neuro-
immunol. 156, 96–106.
33. Maloy, K. J., Salaun, L., Cahill, R., Dougan, G., Saunders, N. J. & Powrie, F.
(2003) J. Exp. Med. 197, 111–119.
Stephens et al. PNAS  November 29, 2005  vol. 102  no. 48  17423
IM
M
U
N
O
LO
G
Y
